Eli Lilly strikes $1.3bn gene therapy deal with Rznomics
Eli Lilly is strengthening its position in genetic medicine for hearing loss through a new collaboration with South Korea-based biotech…
All articles by Jenna Philpott
Jenna Philpott
Jenna Philpott is a news and features reporter for Pharmaceutical Technology. Jenna holds a BSc in Biochemistry and has interests in rare diseases, gene therapies, and oncology. Contact Jenna
-
-
Newborn screening strategy needs modernising as HHS disbands advisory committee
After sweeping cuts to US federal health agencies, the elimination of a committee responsible for recommending newborn screening regulations is…
-
FDA awards cancer drug approvals to AbbVie and MSD
The US Food and Drug Administration (FDA) has approved two oncology drugs: MSD’s Welireg (belzutifan) and AbbVie’s Emrelis (telisotuzumab vedotin-tllv).…
-
AbbVie expands siRNA push with $335m ADARx deal
AbbVie has signed a collaboration and licensing agreement with US-based ADARx Pharmaceuticals, committing $335m upfront to access its small interfering…
-
Novo Nordisk taps Septerna in $2.2bn deal for oral obesity therapies
As competition continues to intensify in the obesity treatment market, Novo Nordisk has struck a collaboration and licencing deal worth…
-
Stylus Medicine launches with $85m to advance in vivo gene editing
Biotech startup Stylus Medicine has launched with $85m in funding to develop a new class of in vivo genetic medicines…
-
Pharma faces 30-day deadline under Trump’s pricing order
US President Donald Trump has signed an executive order aimed at reducing prescription drug prices by linking them to what…
-
Roche plans $700m manufacturing plant in the US
Roche is deepening its manufacturing footprint in the US with plans to invest more than $700m in a new production…
-
Trump to sign order tying US drug prices to global rates
In a renewed push to overhaul pharmaceutical pricing in the US, President Donald Trump announced he will sign an executive…
-
FDA plans to expand unannounced inspections of foreign drug plants
The US Food and Drug Administration (FDA) is moving to tighten oversight of foreign manufacturers supplying the US market by…